Active — Not RecruitingNot Applicable

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

United States300 participantsStarted 2023-09-28

Plain-language summary

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Who can participate

Age range60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Nonsubfoveal lesion(s)
✓. GA lesion visualized in its entirety on the macula-centered OCT image and not contiguous with any areas of peripapillary atrophy

What they're measuring

Incidence of ocular AEs in treated eyes overall and according to physician-directed treatment interval based on US prescribing information

Timeframe: Up to 36 months

Incidence of other events of interest

Timeframe: Up to 36 months

Trial details

NCT IDNCT06161584

SponsorApellis Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-06

View on ClinicalTrials.gov More Geographic Atrophy trials